Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients.

Published on Jan 23, 2020in British Journal of Cancer5.416
· DOI :10.1038/s41416-019-0704-2
Shi-wei Guo1
Estimated H-index: 1
('SMMU': Second Military Medical University),
Xiaohan Shi1
Estimated H-index: 1
('SMMU': Second Military Medical University)
+ 8 AuthorsZhuo Shao5
Estimated H-index: 5
('SMMU': Second Military Medical University)
About 25–37% of resectable pancreatic ductal adenocarcinoma (PDAC) had a great chance of early recurrence after radical resection, which is mainly due to preoperative micrometastasis. We herein demonstrated the profiles of ctDNA in resectable PDAC and use of ctDNA to identify patients with potential micrometastasis. A total of 113 and 44 resectable PDACs were enrolled in discovery and validation cohorts, separately. A panel containing 50 genes was used to screen ctDNA by an NGS-based assessment with high specificity. In the discovery cohort, the overall detection rate was 38.05% (43/113). Among positive ctDNA, KRAS mutation had the highest detection rate (23.01%, 26/113), while the others were <5%. Survival analysis showed that plasma KRAS mutations, especially KRAS G12D mutation, had significant association with OS and RFS of resectable PDAC. Plasma KRAS G12D mutation showed a strong correlation with early distant metastasis. In the validation cohort, survival analysis showed similar association between plasma KRAS G12D mutation and poor outcomes. This study demonstrated that plasma KRAS mutations, especially KRAS G12D mutation, served as a useful predictive biomarker for prognosis of resectable PDAC. More importantly, due to high correlation with micrometastasis, preoperative detection of plasma KRAS G12D mutation helps in optimising surgical selection of resectable PDAC.
  • References (51)
  • Citations (0)
📖 Papers frequently viewed together
20192.78PLOS ONE
5 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Vincent P. Groot (Johns Hopkins University)H-Index: 9
#2Stacy Mosier (Johns Hopkins University)H-Index: 4
Last. James R. Eshleman (Johns Hopkins University)H-Index: 53
view all 27 authors...
Purpose: In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform analytical and clinical validation of a KRAS ctDNA assay in a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathology (CAP) certified clinical laboratory. Experimental Design: Digital-droplet PCR (ddPCR) was used to detect the major PDAC-associated somatic KRAS mutations (G12D, G12V, G12R and Q...
4 CitationsSource
#1R. C. Coombes (Imperial College London)H-Index: 11
#2Karen Page (University of Leicester)H-Index: 10
Last. Jaqueline A. Shaw (University of Leicester)H-Index: 1
view all 39 authors...
Purpose: Up to 30% of breast cancer patients relapse after primary treatment. There are no sensitive and reliable tests to monitor these patients and detect distant metastases before overt recurrence. Here we demonstrate the use of personalized ctDNA profiling for detection of recurrence in breast cancer. Methods: Forty-nine primary breast cancer patients were recruited following surgery and adjuvant therapy. Plasma samples (n=208) were collected every 6 months for up to 4 years. Personalized as...
2 CitationsSource
Purpose of reviewTissue biopsy is the current gold standard technique for diagnosis and molecular profiling of lymphomas, but it carries several disadvantages in terms of procedural risks (infectious and haemorrhagic complications, anaesthesiologic risks) and analytic aspects (heterogeneity of tumor
#1Giulia Siravegna (UNITO: University of Turin)H-Index: 25
#2Andrea Sartore-Bianchi (University of Milan)H-Index: 41
Last. Alberto Bardelli (UNITO: University of Turin)H-Index: 76
view all 10 authors...
Purpose: ERBB2 (HER2) amplification is an emerging biomarker in colon cancer, conferring sensitivity to combination anti-HER2 therapy. Measurement of HER2 copy number is typically performed using surgical specimens, but cell-free circulating tumor DNA (ctDNA) analysis may be a noninvasive alternative. We determined the sensitivity of plasma copy number (pCN) for detecting ERBB2 amplifications and whether pCN correlated with tissue-detected copy number. We also assessed response to HER2-targeted ...
5 CitationsSource
#1Grainne M. O'Kane (Princess Margaret Cancer Centre)H-Index: 7
#2Geoffrey Liu (Princess Margaret Cancer Centre)H-Index: 54
Last. Natasha B. Leighl (Princess Margaret Cancer Centre)H-Index: 48
view all 11 authors...
Abstract Background Peripheral blood sampling for detection of EGFR T790M in cell-free circulating tumour (ct) DNA in TKI-resistant EGFR mutant (EGFRm) lung cancer is now standard. The value of more comprehensive sequencing is unknown. Methods Prospective ctDNA analysis in patients with EGFRm NSCLC was performed using a next generation sequencing (NGS) panel of regions of 11 genes detecting single nucleotide variants and small insertions/deletions at ≥0.1% variant allele frequency (VAF) was perf...
Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free tumour DNA (ctDNA). Highly sensitive liquid biopsy assays have been developed that can now be applied to detect and characterize minimal residual disease (MRD), which reflects the presence of tumour cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological si...
30 CitationsSource
#1Andrew W. Hahn (HCI: Huntsman Cancer Institute)H-Index: 9
#2David D. Stenehjem (UMN: University of Minnesota)H-Index: 8
Last. Neeraj Agarwal (HCI: Huntsman Cancer Institute)H-Index: 37
view all 8 authors...
Abstract Background Targeted therapies have shown promise for men with metastatic castration-resistant prostate cancer (mCRPC). Due to the difficulty with obtaining tumor tissue in bony metastases, liquid biopsies are a promising alternative to guide treatment selection. While concurrent tissue next-generation sequencing (tNGS) and liquid biopsy has high concordance, it is unknown whether the genomic landscape of metastatic prostate cancer (mPC) changes over time or treatment. Herein, we hypothe...
1 CitationsSource
#1Stephan Kruger (LMU: Ludwig Maximilian University of Munich)H-Index: 9
#2Heinemann (LMU: Ludwig Maximilian University of Munich)H-Index: 3
Last. Stefan Holdenrieder (TUM: Technische Universität München)H-Index: 18
view all 15 authors...
The presence of mutated KRAS ((mut)KRAS ctDNA) in plasma samples has been consistently shown to be a negative prognostic indicator in pancreatic cancer (PC). Only small pilot studies have evaluated the value of serial (mut)KRAS ctDNA-measurements in PC. The aim of the present study was to explore the potential of repeated (mut)KRAS ctDNA measurements for response prediction and therapy monitoring in advanced PC patients. We used the BEAMing technology to determine levels of (mut)KRAS ctDNA, CA 1...
5 CitationsSource
#1Thomas John (University of Melbourne)H-Index: 23
#2Hiroaki Akamatsu (Wakayama Medical University)H-Index: 15
Last. Yi-Long WuH-Index: 62
view all 9 authors...
Abstract Objectives: In AURA3 (NCT02151981), osimertinib treatment provided significant clinical benefit compared with platinum-pemetrexed in patients with epidermal growth factor receptor (EGFR) T790M-positive advanced non-small-cell lung cancer (NSCLC), whose tumors had progressed on previous EGFR-tyrosine kinase inhibitor therapy. This retrospective analysis investigated detection rates for T790M, common (exon 19 deletion and L858R), and rare EGFR mutations in tissue samples from the screened...
1 CitationsSource
Cancer is one of the greatest threats facing our society, being the second leading cause of death globally. Currents strategies for cancer diagnosis consist of the extraction of a solid tissue from the affected area. This sample enables the study of specific biomarkers and the genetic nature of the tumor. However, the tissue extraction is risky and painful for the patient and in some cases is unavailable in inaccessible tumors. Moreover, a solid biopsy is expensive and time consuming and cannot ...
18 CitationsSource
Cited By0